The epigenetic reprogramming and changes in expression are due, in part, to the enhancer of zeste homolog 2 (EZH2), an oncogene that is overexpressed in various cancers including prostate, breast, bladder, endometrial, and small-cell lung cancers [14,15]. Here, EZH2 is linked to small cell lung carcinoma.